DRESDEN, Germany, December 15, 2021 / BioInformant / — denovoMATRIX GmbH, an innovator in cell and gene therapy (CGT) manufacturing, announced the launch of a new technology for bringing down costs and increasing access to high-quality mesenchymal stromal cells (MSCs) for stem cell-based therapies. The technology termed isoMATRIX, is designed to isolate MSCs in xeno-/serum-free conditions with high efficiency and stemness enabling rapid cell expansion for radically reduced cost of goods (COGs) for cell therapy manufacturers.
High-quality and low-cost manufacturing is necessary to bring regenerative therapies to patients. Particularly for MSC-based therapies, the low number of cells in the source material and their limited expansion time in addition to the high cost of goods hamper the widespread application of those life-saving treatments.
MSC-based therapies require regular isolation and expansion due to the limited time MSCs can be cultured ex vivo before their therapeutic potential is affected. Furthermore, donor approval, lengthy characterization and the use of good manufacturing practices (GMP) is needed for each lot of isolated MSCs before it can be used in stem cell-based therapies. ‘‘Designed for GMP processes and cell therapies, the isoMATRIX signifies a breakthrough in MSC manufacturing efficiency. The technology significantly increases the number of tissue-isolated MSCs, which raises the cell yield that can be generated from a single donor’’ says Dr. Kristina Thamm, Head of Project Services at denovoMATRIX. ‘‘We see the isoMATRIX as a key opportunity to enable industry players in the MSC therapies space, and would pursue an out-licensing strategy for this technology’’ continues Dr. Dejan Hušman, CEO of denovoMATRIX.
The key innovations of the isoMATRIX are twofold.
Using isoMATRIX to isolate MSCs from bone marrow aspirates or adipose tissue results in up to 35% more isolated cells compared to standard isolation procedures. As shown in the figure, starting the manufacturing process with a higher number of cells results in a strong increase in overall yield, which is the first xeno-/serum-free product to exhibit this behavior. Furthermore, MSCs isolated with the isoMATRIX proliferate on average 33% faster indicating that total manufacturing time can also be reduced. Detailed scientific data supporting these claims can be found here.
About denovoMATRIX GmbH
denovoMATRIX deploys a modular, biomimetic coating technology to enable high performance cell culture, bringing cell therapies to patients and accelerating the path to market for clean meat. The company leverages chemical synthesis, stem cell biology and design thinking to build a platform of biomaterials which address major life science challenges. By providing both cell-based therapy and clean meat companies with solutions, denovoMATRIX is at the forefront of innovation in cell manufacturing processes.
For more information, visit: https://www.denovomatrix.com/isomatrix/
Tell Us What You Think!